Abbott (ABT) announced results from the FreeDM2 randomized controlled trial showing that people using FreeStyle Libre continuous glucose monitoring technology had better glucose outcomes than those using traditional fingersticks. The trial was designed to determine whether real-time continuous glucose monitoring can help people using basal insulin improve their glucose management.
In the U.K. FreeDM2 randomized controlled trial, at four months, people using Libre technology had a 0.6% greater reduction in HbA1c and 2.5 more hours a day in the healthy range vs. fingersticks. Complementary Italian study reported similar improvements, the company said.
In pre-market trading on NYSE, Abbott shares are down 0.61 percent to $109.57.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.